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Background: Toxoplasma retinochoroiditis can have an atypical presentation and be difficult to diagnose in
immunocompromised patients. Accurate diagnosis and appropriate treatment is important since the disease can be
aggressive in these patients. This paper is a case report with literature review, emphasizing on the diagnosis and
treatment of Toxoplasma retinochoroiditis.
Findings: A 27-year-old male with chronic myelogenous leukemia with history of bone marrow transplantation
presented with floaters in his right eye. Fundus exam showed bilateral, multifocal retinochoroiditis with subsequent
development of a mild vitritis. Serum cytomegalovirus and toxoplasmosis antibody titers and syphilis screen were
negative. Aqueous polymerase chain reaction (PCR) analysis revealed the presence of Toxoplasma gondii DNA OU.
Clindamycin (1.0 mg/0.1 mL) was injected bilateral intravitreal OU twice at 4 days apart with subsequent resolution
of retinochoroiditis.
Conclusions: When evaluating retinochoroiditis in an immunocompromised patient, one must keep a high index
of suspicion for atypical presentations of well-known disease entities. Aqueous and vitreous samples for PCR can be
useful in obtaining an accurate diagnosis and therefore provide appropriate management for the patient.
Intravitreal clindamycin is an option for treatment in these patients.
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Summary statement
An immunocompromised patient presented with floaters
and fundus lesions suspicious for infectious retinochor-
oiditis vs. chronic myelogenous leukemia (CML) relapse.
Despite negative serum toxoplasmosis titers, an aqueous
polymerase chain reaction (PCR) analysis revealed ocular
toxoplasmosis bilaterally and the patient responded to
therapy. We discuss clinical presentation, diagnostic
workup, and various treatment options in the manage-
ment of Toxoplasma retinochoroiditis. All research for
this brief report was done with appropriate ethical* Correspondence: dgritz@montefiore.org
2Department of Ophthalmology and Visual Sciences, Montefiore Medical
Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA
3Department of Epidemiology and Population Health, Montefiore Medical
Center and Albert Einstein College of Medicine, Bronx, 111 East 210th St.,
Bronx, NY 10467, USA
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in any medium, provided the original work is papproval from the Albert Einstein College of Medicine
Institutional Review Board and informed consent was
obtained from the subject.
Case description
A 27-year-old male with history of CML on remission
since treatment with imatinib, chemoradiation, and allo-
genic bone marrow transplantation 1 year prior to con-
sultation and with active and recurrent acyclovir-resistant
herpes simplex stomatosis presented with a 2-day history
of floaters in his right eye. Patient’s medications included
several immunosuppressive agents such as tacrolimus, sir-
olimus, and mycophenolate along with the prophylactic
medications, atovaquone, valacyclovir, and ciprofloxacin.
Visual acuity was 20/30 +3 and 20/100 in the right and left
eyes, respectively. Fundus examination of the right eye
revealed irregular, fluffy, white subretinal and intraretinal
lesions with pigmentary changes in the superotemporal
arcade (Figure 1a). In the left eye, a smaller similar lesionn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Fundus examination of the right eye. Fluffy white retinal infiltrates with mild hemorrhage superotemporal to macula in right eye (a)
and peripapillary infiltrate in left eye (b).
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adjacent retinal edema involving the macula. No vitritis
was noted bilaterally. Differential diagnosis included viral
retinochoroiditis (cytomegalovirus (CMV), herpes simplex
virus (HSV), and varicella zoster virus (VZV)) vs. CML
relapse vs. atypical toxoplasmosis (Figure 1b).
Serum IgM and IgG titers for CMV and toxoplasmosis
were negative in addition to syphilis screening being
negative. Cerebrospinal fluid (CSF) analysis was negative
for CMV, HSV, toxoplasmosis via PCR, and bacterial
growth. CSF analysis also showed atypical cells with no
blasts indicating no evidence of CML relapse. MRI
brain/orbits showed no abnormalities. Intravenous cido-
fovir had recently been started for HSV stomatitis, and
the patient was initially observed on this treatment.
Two weeks after presentation, visual acuity decreased to
20/70 OD and 20/400 OS. Examination revealed progres-
sion of the retinal lesions with a mild vitritis (Figure 2).
The clinical picture was highly suspicious for CMV retin-
itis; however, the negative serum CMV PCR and progres-
sion of lesions on cidofovir raised serious doubt. An
anterior chamber paracentesis was performed, and the
aqueous humor was sent for PCR for CMV, HSV, VZV,
Epstein-Barr virus (EBV), and toxoplasmosis. A moreFigure 2 Progression of the retinal lesions with a mild vitritis. Increase
peripapillary infiltrate with new adjacent retinal hemorrhages in the left eye
unfortunately, not visible in photos.aggressive treatment of the CMV retinitis was also pur-
sued with bilateral intravitreal injections of foscarnet in
addition to intravenous route.
Five days later, quantitative PCR analysis revealed
3,400 DNA copies/ml OD and 2,800 DNA copies/ml OS
of Toxoplasma gondii and negative PCR for HSV, VZV,
EBV, and CMV OU. A diagnosis of Toxoplasma retino-
chorioditis was made. Clindamycin (1.0 mg/0.1 mL) was
injected intravitreally OU twice at 4 days apart. Over the
next month, the active areas of retinochoroiditis regressed
followed by gliosis of the lesions with pigmentary
changes (Figure 3a,b). The vision subsequently improved
to 20/50 OD and 20/100 OS. Patient was also started on
trimethoprim-sulfamethoxazole to prevent future reacti-
vation of the disease.
Discussion
This case report describes a patient with Toxoplasma
retinochoroiditis masquerading as a viral infection in a
patient with chronic myelogenous leukemia. Initial clinical
examination and laboratory values lead to a presumptive
diagnosis of a viral retinochorioditis, and treatment with
both intravitreal and systemic foscarnet was initiated in
addition to oral cidofovir. Disease progression was notedd density and size of infiltrates in the right eye (a) enlarging the
(b). There were suggestions of subretinal inflammation clinically, but
Figure 3 Note granular appearance of lesions with gliosis indicating resolving retinochoroiditis, in both the right eye (a) and left eye (b).
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aqueous tap sent for PCR analysis confirmed the diagnosis
of toxoplasmosis and the patient was successfully treated
with intravitreal injections of clindamycin.
It may be difficult to clinically distinguish toxoplasmo-
sis infection among the different causes of infectious
retinochoroiditis; however, such a distinction has im-
portant therapeutic implications. It has been described
that when contrasted to CMV retinochoroiditis, retinal
lesions of toxoplasmosis are thicker and more densely
opaque with smooth and non-granular lesion borders
which are often associated with a chorioretinal scar [1].
Subretinal fluid in association with retinochoroiditis is
more commonly seen in toxoplasmosis [2]. Prominent
inflammatory reactions, anterior and posterior, are a
hallmark of Toxoplasma retinochoroiditis [1]. However,
in immunocompromised patients, the inflammatory re-
action may not be as robust, thereby diminishing the
sensitivity of this difference. Additionally, one of the
most interesting aspects of this case was the negative
serum and CSF toxoplamosis serology, which swayed the
diagnosis away, until the results of the aqueous PCR
were received. Again, the negative serology may have
been due to the poor immune function of this patient
with a history of CML s/p bone marrow transplantation.
Furthermore, the rapid progression of the disease
process in this patient is atypical for toxoplasmosis.
Toxoplasmosis may present bilaterally with rapid pro-
gression, without impressive inflammation and a negative
serum serology, in immunocompromised patients. Thus, a
high index of suspicion is needed to make the diagnosis of
Toxoplasma retinochoroiditis in such patients.
Treatment for this patient was with two sets of bilateral
intravitreal injections of clindamycin (1.0 mg/0.1 mL). It
has been shown that intravitreal clindamycin plus dexa-
methasone has similar outcomes to classic therapy (pyri-
methamine, sulfadiazine, and prednisolone) for Toxoplasma
retinochoroiditis in terms of the ability to reduce lesion
size and vitreal inflammation as well as improve visualacuity [3,4]. Because of issues with follow-up, the two
injections were given 4 days apart. The patient responded
to only two injections so well, that he was simply observed
at that point.
Oral clindamycin has also been used in the treatment
of Toxoplasma retinochoroiditis. Some use it as part of a
quadruple therapy in immunocompetent patients, which
consists of classic therapy plus oral clindamycin [5]. It
has also been shown that oral clindamycin alone is
effective in treating Toxoplasma retinochoroiditis with
minimal side effects [6].
Intravitreal administration of clindamycin has advan-
tages over classic therapy due to its reduced side effect
profile. Intravitreal injections of clindamycin deliver a
high concentration of the medicine to the intraocular
tissues while reducing systemic absorption and un-
wanted systemic side effects. Additionally, the clindamy-
cin’s good intracellular penetration makes it a good
antimicrobial choice for the intracellular T. gondii. Several
studies have shown clindamycin to be non-toxic to the
retina [3]. Nevertheless, the risks of an intravitreal injec-
tion itself do remain including endophthalmitis and retinal
detachment [7,8]. Furthermore, intravitreal clindamycin
will only treat the ophthalmic disease, but it will not treat
nor prevent systemic reactivation of toxoplasmosis.
Another appropriate treatment for ocular toxoplasmosis
is trimethoprim-sulfamethoxazole (TMP-SMX). It has
been shown that TMP-SMX has similar efficacy in terms
of reduction in the retinal lesion size and improvement in
visual acuity and has preferred side effect profile com-
pared to pyrimethamine and sulfadiazine [9]. Given as an
oral medication, it will provide prophylaxis for systemic
reactivation of the disease as well.
Multiple different regimens have been shown to be
effective in treating toxoplasmosis retinochoroiditis in
immunocompromised patients, none of which proving to
be superior. In contrast to immunocompromised patients
in whom treatment is crucial, it is not established that im-
munocompetent patients require therapy.
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Toxoplasmosis should be included in the differential diag-
nosis of a retinochoroiditis in an immunocompromised
patient even if it presents without the typical inflamma-
tory response, an adjacent chorioretinal scar, typical retin-
itis, or is bilaterally active. If the CSF and serum serologies
are negative, this should not sway the diagnosis away from
toxoplasmosis in the immunocompromised patients. One
should consider an aqueous tap for PCR analysis to aid in
the diagnosis of the disease process. Once the diagnosis is
confirmed, appropriate therapy may be promptly insti-
tuted in hopes of preserving the maximal vision.
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